JP2017524031A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524031A5
JP2017524031A5 JP2017521620A JP2017521620A JP2017524031A5 JP 2017524031 A5 JP2017524031 A5 JP 2017524031A5 JP 2017521620 A JP2017521620 A JP 2017521620A JP 2017521620 A JP2017521620 A JP 2017521620A JP 2017524031 A5 JP2017524031 A5 JP 2017524031A5
Authority
JP
Japan
Prior art keywords
cells
subject
gamma delta
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017521620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524031A (ja
Filing date
Publication date
Priority claimed from GB201412175A external-priority patent/GB201412175D0/en
Priority claimed from GB201415379A external-priority patent/GB201415379D0/en
Priority claimed from GBGB1506423.1A external-priority patent/GB201506423D0/en
Application filed filed Critical
Priority claimed from PCT/GB2015/051985 external-priority patent/WO2016005752A1/en
Publication of JP2017524031A publication Critical patent/JP2017524031A/ja
Publication of JP2017524031A5 publication Critical patent/JP2017524031A5/ja
Pending legal-status Critical Current

Links

JP2017521620A 2014-07-09 2015-07-08 ガンマデルタt細胞およびその使用 Pending JP2017524031A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201412175A GB201412175D0 (en) 2014-07-09 2014-07-09 Gamma T cells and uses thereof
GB1412175.0 2014-07-09
GB1415379.5 2014-08-29
GB201415379A GB201415379D0 (en) 2014-08-29 2014-08-29 Gamma T cells and uses thereof
GBGB1506423.1A GB201506423D0 (en) 2015-04-15 2015-04-15 Gamma delta T cells and uses thereof
GB1506423.1 2015-04-15
PCT/GB2015/051985 WO2016005752A1 (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020115432A Division JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタt細胞およびその使用

Publications (2)

Publication Number Publication Date
JP2017524031A JP2017524031A (ja) 2017-08-24
JP2017524031A5 true JP2017524031A5 (enExample) 2018-08-16

Family

ID=53776892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017521620A Pending JP2017524031A (ja) 2014-07-09 2015-07-08 ガンマデルタt細胞およびその使用
JP2020115432A Pending JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタt細胞およびその使用
JP2023088259A Pending JP2023123437A (ja) 2014-07-09 2023-05-29 ガンマデルタt細胞およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020115432A Pending JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタt細胞およびその使用
JP2023088259A Pending JP2023123437A (ja) 2014-07-09 2023-05-29 ガンマデルタt細胞およびその使用

Country Status (12)

Country Link
US (2) US20170196910A1 (enExample)
EP (1) EP3167050A1 (enExample)
JP (3) JP2017524031A (enExample)
KR (1) KR20170045205A (enExample)
CN (1) CN107075480A (enExample)
AU (1) AU2015287456A1 (enExample)
BR (1) BR112017000464A2 (enExample)
CA (1) CA2954546A1 (enExample)
EA (1) EA201790010A1 (enExample)
IL (1) IL249970B (enExample)
SG (1) SG11201700134PA (enExample)
WO (1) WO2016005752A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
CN107106578B (zh) * 2014-08-12 2020-12-25 香港大学 治疗厄泼斯坦-巴尔病毒相关疾病的双膦酸盐化合物和γδT细胞-介导的疗法
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
US20180028566A1 (en) * 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US20200172864A1 (en) * 2016-09-26 2020-06-04 Tessa Therapeutics Ltd. T Cell Expansion Method
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
US10519236B2 (en) 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
CN112930187A (zh) * 2018-09-27 2021-06-08 弗斯弗加姆股份有限公司 用于同种异体γ/δ-T细胞的扩增和使用的方法和组合物
BR112021006254A2 (pt) 2018-10-01 2021-07-27 Adicet Bio, Inc. composições e métodos relativos a células t¿d engenheiradas e não engenheiradas para tratamento de tumores sólidos
JP7687952B2 (ja) 2018-10-01 2025-06-03 アディセット セラピューティクス, インク. 血液腫瘍を治療するための遺伝子操作しているγδ-T細胞及び遺伝子操作していないγδ-T細胞に関する組成物及び方法
WO2020154548A2 (en) 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
CN114555785B (zh) * 2019-10-17 2024-12-06 香港大学 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法
WO2021178890A1 (en) 2020-03-06 2021-09-10 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
EP4183871A1 (en) 2021-11-23 2023-05-24 Université d'Aix-Marseille Process for preparing a composition comprising a combined cell population
KR20230105166A (ko) * 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
MX2024010047A (es) 2022-02-16 2024-08-26 Priothera Sas Metodos de tratamiento con celulas car en combinacion con moduladores del receptor s1p.
DE102022132084B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
DE102022132082B4 (de) 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
DE102022132083B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
WO2025046256A1 (en) 2023-08-31 2025-03-06 Universite D'aix-Marseille Process for preparing a composition comprising a combined cell population

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360046A1 (en) * 1999-01-28 2000-08-03 Lawrence S. Lamb, Jr. In vitro activated gamma delta lymphocytes
AU4816201A (en) * 2000-04-03 2001-10-15 Hemosol Inc Production of tcr gamma delta t cells
ES2250480T3 (es) 2000-09-11 2006-04-16 Chiron Corporation Derivados de quinolinona como inhibidores de tirosina quinasa.
JPWO2006006720A1 (ja) 2004-07-13 2008-05-01 株式会社メディネット γδT細胞の培養方法、γδT細胞及び治療・予防剤
CA2576571C (en) * 2004-08-19 2013-07-02 University Of Bern Preparation of antigen-presenting human .gamma..delta. t cells and use in immunotherapy
ES2350895T3 (es) * 2004-08-19 2011-01-28 University College Cardiff Consultants Limited Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia.
ES2391573T3 (es) 2005-09-08 2012-11-27 Medinet Co., Ltd. Método para el tratamiento de activación de una célula presentadora de antígeno
JPWO2008152822A1 (ja) * 2007-06-15 2010-08-26 株式会社メディネット 医薬

Similar Documents

Publication Publication Date Title
JP2017524031A5 (enExample)
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
HK1203489A1 (en) Purinone compounds as kinase inhibitors
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112022008750A2 (pt) Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
EP4353254A3 (en) Methods for treating skin infection by administering an il-4r antagonist
MX2016014548A (es) Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa.
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
MX2018012945A (es) Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre.
FR2958163B1 (fr) Preparation issue d'une culture in vitro de cellules dedifferencieres non elicitees d'arganier, leur utilisation pour le traitement du vieillissement cutane, de l'inflammation et de la cicatrisation, et leur obtention.
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
WO2016048861A3 (en) Heterocyclic compounds and use thereof
GB201013215D0 (en) Expression of antibody or a fragment thereof in lactobacillus
BR112019000837A2 (pt) células miméticas de célula b
WO2019113375A3 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
MX382563B (es) Formas cristalinas de bilastina y procedimientos para su preparacion.
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.